Acceptability and usefulness of mizoribine in the management of rheumatoid arthritis in methotrexate-refractory patients and elderly patients, based on analysis of data from a large-scale observational cohort study

References

• Abe T. Lesson from ACR guidelines for management of RA (in Japanese). Nippon Rinsho 2005;63(Suppl 1):431–8.
   PubMedGoogle Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328–46.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Yamanaka H. Methotrexate as a standard drug for rheumatoid arthritis (in Japanese). Rheumatology 2004;32(3):223–8.
   Google Scholar
• Nishiyama S, Miyawaki S. A study on usage of methotrexate (in Japanese). Clin Rheumatol 2003;15(3):213–9.
   Google Scholar
• Suzuki Y, Wakabayashi T, Jackson K. Methotrexate for therapy of rheumatoid arthritis (in Japanese). Nippon Rinsho 2005;63(Suppl 1):498–502.
   Google Scholar
• Kashiwazaki S, Kondo H, Koike T, Saito T, Kasukawa R, Kasiwagi H, et al. Dose comparison study with Bredinin tablets in the management of rheumatoid arthritis (in Japanese). Jan J Inflammation 1996;16(4):269–89.
   Google Scholar
• Shiokawa Y, Honma M, Shichikawa K, Miyamoto T, Hirose J, Nobunaga T, et al. A double-blind comparative trial of mizoribine in the treatment of rheumatoid arthritis (in Japanese). Jpn J Inflamm 1991;11(4):375–96.
   Google Scholar
• Koyama H, Tsuji M. Genetic and biochemical studies on the activation and cytotoxic mechanism of Bredinin, A potent inhibitor of purine biosynthesis in mammalian cells. Biochem Pharmacol 1983;32(23):3547–53.
   PubMed Web of Science ®Google Scholar
• Kusumi T, Tsuda M, Katsunuma T, Yamamura M. Dual inhibitory effect of Breinin. Cell Biochem Funct 1988;7:201–4.
   Web of Science ®Google Scholar
• Shiokawa Y, Honma M, Shichikawa K, Miyamoto T, Hirose J, Nobunaga M, et al. Clinical evaluation of an immunosuppressant mizoribine in the treatment of rheumatoid arthritis (in Japanese). J Clin Exp Med 1991;156(12):811–31.
   Google Scholar
• Yamanaka H, Tohma S. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol 2006;16(2):75–6.
   PubMedGoogle Scholar
• Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3763 patients with rheumatoid arthritis. Arthritis Rheum 2003;49:784–8.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Ortendahl M, Schettler JD, Fries JF. Factors influencing length of time taking methotrexate in rheumatoid arthritis. J Rheumatol 2000;27(5):1139–47.
   Google Scholar
• Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem 1999;6:575–97.
   PubMed Web of Science ®Google Scholar
• Gan L, Seyedsayamdost MR, Shuto S, Matsuda A, Petsko GA, Hedstrom L. The immunosuppressive agent mizoribine monophosphate forms a transition state analogue complex with inosine monophosphate dehydrogenase. Biochemistry 2003;42(4):857–63.
   PubMed Web of Science ®Google Scholar
• Yoshida T. A study of the inhibitory effect of mizoribinemethotrexate combination on osteoclast formation (in Japanese). In: Collection of Abstracts of Papers Presented at the 48th Conference of Japan Rheumatism Association. WO23-5, 2004. p. 191.
   Google Scholar
• Azuma H, Ohkubo Y, Shindoh H, Nohara Y, Yamada H. A study on mizoribine dosage and administration in rheumatoid arthritis (in Japanese). J New Remedies Clinics 1997;46(12):275–85.
   Google Scholar
• Inoue H, Iso T, Sakurai T. Assessments of usefulness of concomitant mizoribine adjunctive therapy in inadequate responders (in Japanese). Clin Rheumatol 1999;11:284–91.
   Google Scholar
• Kikuchi H, Sohen S, Tan A, Kamiya M, Hamanishi C, Tanaka S. A study on mizoribine adjunctive therapy in rheumatoid arthritis patients receiving bucillamine (in Japanese). Clin Rheumatol 1997;9(1):44–9.
   Google Scholar
• Kohriyama K, Hiramatsu Y, Aoyama K. A trial of methotrexatemizoribine combination pulse therapy in patients with rheumatoid arthritis refractory to low-dose methotrexate (in Japanese). Clin Rheumatol 2003;15(3):227.
   Google Scholar
• Kosakai O, Ooki M, Shitoto K. Combination treatment with actarit and mizoribine in patients with early-stage rheumatoid arthritis (in Japanese). Rheumatology 1997;17(5):554–8.
   Google Scholar
• Mori Y, Okumo H, Kubo M, Kuroki Y. Combined bucillaminemizoribine therapy for rheumatoid arthritis (in Japanese). Clin Rheumatol 1995;7:89–93.
   Google Scholar
• Tokuda M, Dobashi H, Hiraishi T, Mitsunaka H, Takahara J, Hirohata M. Low-dose concomitant mizoribine pulse therapy for methotrexate-refractory rheumatoid arthritis (in Japanese). Rheumatology 1998;20(5):519–26.
   Google Scholar
• Ueki Y, Miyake S, Matsumoto K, Yano M, Tominaga Y, Yamaguchi Y, et al. Assessments of usefulness of concomitant mizoribine adjunctive therapy for rheumatoid arthritis in inadequate responders to bucillamine (in Japanese). Kyushu Ryumachi 1999;18:1–7.
   Google Scholar
• Kondo H, Koike T, Saito T, Kasukawa R, Kasiwagi H, Akizuki M, et al. Dose comparison study with Bredinin tablets in the management of rheumatoid arthritis (2) (in Japanese). Jpn J Inflamm 1998;18(1):61–80.
   Google Scholar
• Urano F, Ono S, Suzuki S. Therapeutic experience with mizoribine in the treatment of rheumatoid arthritis (RA) in elderly patients (in Japanese). Chubu Ryumachi 2004;35(2):132–3.
   Google Scholar
• Takada K, Muranishi S, Yoshikawa H, Asada S, Takahara S, Nagano S, et al. A clinical pharmacokinetic study of Bredinin in patients with renal transplantation (in Japanese). Transplantation 1982:17(Suppl):595–601.
   Google Scholar